Evidence map›Paper›PMID 39541620›Full record

ReviewESMO open2024

Long-term outcomes of PARP inhibitors in ovarian cancer: survival, adverse events, and post-progression insights.

V Tuninetti, J A Marín-Jiménez, G Valabrega, E Ghisoni

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Symptom burden and symptom clusters in ovarian cancer patients during first-line maintenance therapy: a cross-sectional survey.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
  10. Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.medRxiv : the preprint server for health sciences · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

V TuninettiDepartment of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy.
J A Marín-JiménezDepartment of Medical Oncology, Catalan Institute of Oncology (ICO), Barcelona, Spain; Cancer Immunotherapy Group, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
G ValabregaDepartment of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy.
E GhisoniDepartment of Oncology, Immuno-Oncology Service, University Hospital of Lausanne (CHUV-UNIL), Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland; Agora Cancer Research Center, Lausanne, Switzerland. Electronic address: eleonora.ghisoni@chuv.ch.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Poly-ADP-ribose polymerase inhibitors (PARPis) have revolutionized the management of BRCA-mutated (BRCA

Indexed as

Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsDisease ProgressionFemaleHumansTreatment OutcomePoly(ADP-ribose) Polymerase Inhibitorsmyelodysplastic syndromeovarian canceroverall survivalPARP inhibitorspost-progressiontoxicity

Identifiers

PMID39541620
PMCPMC11613435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.